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1073-170 Improved In-Hospita l  Outcomes After Percutaneous  
Coronary Intervention in the Era of Routine 
Glycoprotein l ib/I l ia Inh ib i t ion  and Stant ing  
Cynthia A. Jackevicius. Karen Mackie, Peter Seidelin, Steve Minor, Paul Daly, Alan 
Barolet, Leonard Schwartz, Peter McLaughlin, Doug Ing, John Ross, Vlad Dzavik, 
University Health Network, Toronto, Ontario, Canada. 
Background: Clinical trials have shown that stenting improves clinical outcomes in 
patients undergoing percutaneous coronary intervention (PCI). More recently, clinical tri- 
als have demonstrated the benefit of Glycoprotein lib/Ilia Inhibitor (GPI) therapy in the 
setting of PCI in further reducing adverse cardiac outcomes. Using a PCI database at a 
large tertiary care institution, our objectives were to conduct a practice pattern analysis to 
assess a selected vs routine strategy of GPI and stant use in the prevention of adverse 
cardiac outcomes post-PCI. 
Methods: All patients who underwent PCI at the institution from March 1994 to March 
2001 were part of the cohort. Patients were divided into 3 cohorts: pre-GPI + selected 
stant use, selected GPI + routine stant usa, and routine GPI + stent use. A multivariate 
logistic regression model was constructed using 3 time variables to represent the differ- 
ent strategy periods, with the rate of in-hospital myocardial infarction, death or abrupt clo- 
sure as the primary composite andpoint. The models were adjusted for age, gender, 
diabetes, case urgency and lesion type. 
Results: The cohort consisted of 9,739 patients, 3,476, 4,429, and 1,832 in periods (P) 
1,2, and 3 respectively. 73% of the cohort were male and the mean age (+/-sd) was 
60.9+/-11.4 years. Stent use increased from 33.5% in P1 to 80.6% in P2 and 90.8% in 
P3. GPI use increased from 0% in P1 to 16.4% in P2 and 90.5% in P3. There was a sig- 
nificant difference in the unadjusted composite endpoint between the three periods 
(4.34% vs 3.16% vs 2.51%, respectively for P1, P2, P3; p<0.001). In the multivariate 
regression analysis, the composite endpolnt was significantly greater in P1 and P2 as 
compared to P3 (OR [P1 vs P3] = 2.28, p<0.001; OR [P2 vs P3]=1.43, p=0.049). The rate 
of bleeding complications requiring medical therapy or prolonging hospital stay signifi- 
cantly decreased between PI and P3. 
Conclusions: A significant reduction in adverse cardiac outcomes was observed in asso- 
ciation with a strategy of routine use of GPI therapy and stanting in a large consecutive 
PCI cohort. This finding remained significant after adjusting for changes in potentially 
confounding patient characteristics between the periods assessed. 
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1098-164 Cost -E f fect iveness  of  C-React ive Protein Screening to  
Target Stat in Therapy 
Gavin J. Blake. Paul M. Ridker, Karen M. Kuntz, Brigham and Women's Hospital, Boston, 
Massachusetts, Harvard Schoo/ of Public Health, Boston, Massachusetts. 
Background: StaUn therapy has been shown to reduce coronary event rates among 
individuals with elevated C-reactive protein (CRP) levels but without overt hypedipi- 
demia. 
Methods: We used a Markov model to estimate the incremental cost-effectiveness of 
CRP screening followed by targeted statin therapy for elevated CRP levels compared to 
diet alone for the primary prevention of myocardial infarction (MI) and stroke among indi- 
viduals without overt hyperlipidemia. A societal perspective was used. 
Results: The incremental cost-effectiveness ratio for the CRP screening strategy fol- 
lowed by targeted statin therapy compared with diet alone was $39.500/quality-adjusted 
life year (QALY) for 58-year-old men and $61.200/QALY for 58-year-old women. CRP 
screening was most cost-effective for 75-year-old men ($31,900/QALY) and least cost- 
effective for 35-year-old women ($134,200/QALY). Our results were most sensitive to the 
relative risk of MI, the cost of statin therapy, and the efficacy of statin therapy for prevent- 
ing MI in individuals with high CRP levels. If a higher risk population is considered, or the 
cost of statin therapy is reduced, the cost-effectiveness ratios of CRP screening improve 
significantly, and in some circumstances may be cost-saving. 
Conclusion: CRP screening to target statin therapy for the primary prevention of cardio- 
vascular disease among individuals without overt hypedipidemia may be relatively cost- 
effective for middle-aged men and high-risk middle-aged women. 
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1098-163 Cardiovascular Features and Prognosis of Middle-Aged 
and Elderly Adults With Renal Dysfunction: The Strong 
Heart Study 
Jonathan N. BeUa, Jennifer E. Liu, Mary J. Roman, David C. Robbins, Thomas K. Welt,/, 
Jay Sosenko, Andrew Narva, Philip Zager, Richard R. Fabsifz, Elisa T. Lee, Barbara V. 
Howard, Richard B. Devereux, The New York Presbyterian Hospita/-WeN Medica/ 
Co/lege of Come//Universi~ New York, New York, Bronx-Lebanon Hospita/ Center- 
A/bert Einstein College of Medicine, Bronx, New York. 
Background: The spectrum of cardiac abnormalities and their impact on prognosis in 
adults with renal dysfunction have not been elucidated in population-based samples. 
Methods: Echocardiograms were analyzed in 2,907 American Indian participants in the 
second Strong Heart Study (SHS) examination who had normal renal function (NRF), 
332 with mild renal dysfunction (microalbuminuria or creatinine>l.8 mg/dl, [MRD]) and 
206 with moderate to severe renal dysfunction (macroalbuminuria or on dialysis, [SRD]). 
Results: There were no differences among subgroups in gender, age or body mass index 
(BMI). Compared to SHS participants with NRF, those with M or SRD had higher systolic 
(141±23 and 152±26 vs. 127±18 mmHg) and diastolic blood pressures (BP) (77±12 and 
77±12 vs. 75±10 mmHg, all p<0.001). There was a stepwise increase in heart rate in 
those with MRD (70±11) and SRD (73±10) from those with NRF (68±11 bpm, all 
p<0.001). Mean LV mass, adjusted for gender, age, BMI and systolic BP, was signifi- 
cantly higher in SHS participants with M or SRD (171 and 196 vs. 156 g, all p<0.001 ), as 
was mean relative wall thickness, adjusted for gender, age, BMI, systolic BP and heart 
rate (0.36 and 0.36 vs. 0.35, all p<0.05). Mean ejection fraction, adjusted for gender, age, 
BMI, SBP and LV mass, was lower in those with SRD compared to those with NRF or 
MRD (56 vs. 63 and 62% p<0.05), as was mean adjusted stress-corrected midwall short- 
ening (98 vs. 105 and 102%, p<0 01). SHS participants with M or SRD had lower mean F_J 
A, adjusted for gender, age. BMI, systolic BP and LV mass (0.85 and 0.80 vs. 0.91, 
p<0.001), indicating more impaired diastolic relaxation. The prevalences of LV wall 
motion abnormalities increased stepwise in SHS participants with NRF (7%) to MRD 
(15%) and SRD groups (32%, p<0.001). Incidences of all-cause death (14 and 29 vs. 
6%) and cardiovascular death (5 and 14 vs. 2%, all p<0.01) were higher in participants 
with MRD and SRD. Conclusion: In a population-based sample of middle-aged and aid* 
edy adults, abnormalities in left ventricular structure, systolic and diastolic function 
increased with severity of renal dysfunction, which may contribute to the high mortality 
associated with renal disease. 
1098-165 Clinical Trials Do Not Support Strong Association of 
Beta-Blocker Therapy With Fatigue, Depression, or 
Sexual Dysfunction 
Dennis T. Ko, Patricia R. Hebert, Christopher Coffey, Art Sedrakyan, Jeptha Curtis, 
Harlan M. Krumholz, Ya/e University School of Medicine, New Haven, Connecticut. 
Background: Beta-blocker (BB) therapy remains substantially underutilized in cardiac 
patients despite its proven mortality benefits. Reluctance to prescribe these agents and 
withdrawal of them may derive from concerns about their association with fatigue, 
depression and sexual dysfunction. 
Methods; We sought to review systematically the clinical trial evidence that BBs are 
associated with these adverse effects by performing a quantitative overview of random- 
ized placebo-controlled trials of BBs in myocardial infarction (MI), heart failure (HF) and 
hypertension (HTN). We used the general variance-basod method to combine results 
from individual trials and calculate unbiased estimates of the risks of fatigue, depression, 
and sexual dysfunction associated with BB therapy. 
Results: A total of 13 randomized placebo-controlled trials reported information about 
the adverse effects and studied BBs that are currently approved by the Food and Drug 
Administration for treatment of MI, HF or HTN. These trials included over 30,000 patients 
and followed patients from 6 to 59 mos. Patients assigned to long-term BB therapy expe- 
rienced small significant increases in the risks of fatigue (RR 1.09; 95% CI 1.05,1.14) and 
sexual dysfunction (RR 1.07; 95% CI 1.01,1.15), but not depression (RR 1.03; 95% CI 
0.96,1.11 ). There was a slight suggestion of heterogeneity among the trials, confined to a 
few older trials, all of which had higher relative risk estimates for the adverse effects than 
did the remaining trials. No heterogeneity was observed when the analysis was restricted 
to later generation BB trials. 
Conclusions: Long-term BB therapy is associated with very small increased risks of 
fatigue and sexual dysfunction, but not depression. Conventional wisdom that BB ther- 
apy is associated with substantial increases in the risks of these symptoms is not sub- 
stantiated by data from the clinical trials. 
1098-166 Speci f ic  Polymorphism Groups Within a PPARg-ABCA1 
Pathway Are Associated With Future Death or 
Myocardial In farct ion in Pat ients  With Angiogrephically 
Documented Coronary Artery Disease 
Corv A. Kina. Joseph B. Muhlestein, Noal I. Hart, Jill B. Faatz, Henri O. F. Mulhuizen, 
Jeffrey L. Anderson, Bryant M. Whiting, Benjamin D. Home, John F. Cadquist, LDS 
Hospifa/, Salt Lake City, Utah, University of Utah, Salt Lake Ci~ Utah. 
Background: Peroxisome proliferator-activatad receptor-y (PPAR-y) is a nuclear recep- 
tor that regulates lipid, glucose and insulin metabolism. It has been shown to have a reg- 
ulatory effect on cholesterol efflux through induction of the ATP-Binding Cassette 
Transporter I (ABCA1) gene. Because gone polymorphisms may be associated with ele- 
vated disease risk, we evaluated two common variants, one in the PPARy gene (C161T) 
and one in the ABCA1 gene (G596A), individually and in combination, for an association 
with future death or MI in patients with known coronary artery disease(CAD). 
Methods: DNA was extracted from peripheral blood obtained from 2,060 consenting 
patients undergoing coronary angiography who were enrolled into the catheterization 
